Modified dosing schedules may limit the side effects and are being investigated, noted Dr. Aleksandar Sekulic of the Mayo Clinic, who led the BCC study. In the phase II trial, 30 percent of patients with metastatic disease had a partial response, and 43 percent of patients with locally advanced disease had a complete or partial response. The study included 104 patients.
Tags: complete response, dosing schedules, Dr. Aleksander Sekulic, NCI Bulletin, partial response, Preventive Medicine, Research